Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYTyphoid vs Typbar TCV in Healthy Nepalese Participants
NCT03933098Phase 3Unknown
- Sponsor
- International Vaccine Institute
- Start
- Nov 2019
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Typhoid conjugate vaccine Vi-DT in typhoid fever (4 arms), sponsored by International Vaccine Institute. Primary endpoints: Seroconversion rate of anti-Vi IgG at 4 weeks and Geometric Mean Titers of anti-Vi IgG at 4 weeks. Status: unknown.
02
Drugs
Typhoid conjugate vaccine Vi-DT
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT03933098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933098.